Osteoarthritis (OA) has become a major public health problem not only because of its increasing prevalence worldwide but also because of its frequent association with cardiovascular disease, the leading cause of death in industrialized countries. There is growing evidence that OA is not simply a disease related to aging or mechanical stress of joints but rather a “metabolic disorder” in which various interrelated lipid, metabolic, and humoral mediators contribute to the initiation and progression of the disease process. Indeed, OA has been linked not only to obesity but also to other cardiovascular risk factors, namely, diabetes, dyslipidemia, hypertension, and insulin resistance.
Get full access to this article
View all access options for this article.
References
1.
SinghG, MillerJD, LeeFH, PettittD, RussellMW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: Data from the Third National Health and Nutrition Examination Survey. Am J Manag Care, 2002; 8,15 suppl:S383–S391.
2.
LawrenceRC, FelsonDT, HelmickCG, ArnoldLM, ChoiH, DeyoRA, GabrielS, HirschR, HochbergMC, HunderGG, JordanJM, KatzJN, KremersHM, WolfeF. National Arthritis Data Workgroup. National Arthritis Data Work-group. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum, 2008; 58:26–35.
3.
FelsonDT, ZhangY. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum, 1998; 41:1343–1355.
4.
OliveriaSA, FelsonDT, ReedJI, CirilloPA, WalkerAM. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum, 1995; 38:1134–1141.
5.
PuenpatomRA, TimothyW, VictorTW. Increased Prevalence of Metabolic Syndrome in Individuals with Osteoarthritis: An Analysis of NHANES III Data. Postgrad Med, 2009; 121:9–20.
6.
GandhiR, RazakF, TsoP, DaveyJR, MahomedNN. Asian ethnicity and the prevalence of metabolic syndrome in the osteoarthritic total knee arthroplasty population. J Arthroplasty, 2009[Epub ahead of print].
7.
CerhanJR, WallaceRB, el-KhouryGY, MooreTE, LongCR. Decreased survival with increasing prevalence of full-body, radiographically defined osteoarthritis in women. Am J Epidemiol, 1995; 141:225–234.
HaaraMM, ManninenP, KrogerH, ArokoskiJP, KarkkainenA, KnektP, AromaaA, HeliovaaraM, AromaaA, HeliovaaraM. Osteoarthritis of finger joints in Finns aged 30 or over: prevalence, determinants, and association with mortality. Ann Rheum Dis, 2003; 62:151–158.
10.
SharifM, ElsonCJ, DieppePA, KirwanJR. Elevated serum C-reactive protein levels in osteoarthritis. Br J Rheumatol, 1997; 36:140–141.
11.
ConrozierT, CarlierMC, MathieuP, ColsonF, DebardAL, RichardS, FavretH, BienvenuJ, VignonE. Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study. Ann Rheum Dis, 2000; 59:828–831.
12.
SturmerT, BrennerH, KoenigW, GuntherKP. Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein. Annals Rheum Dis, 2004; 63:200–205.
13.
SowersM, JannauschM, SteinE, JamadarD, HochbergM, LachanceL. C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis Cartilage, 2002; 10:595–601.
14.
KrausVB, StablerTV, LutaG, RennerJB, DragomirAD, JordanJM. Interpretation of serum C-reactive protein (CRP) levels for cardiovascular disease risk is complicated by race, pulmonary disease, body mass index, gender, and osteoarthritis. Osteoarthritis Cartilage, 2007; 15:966–971.
15.
SharifM, ShepstoneL, ElsonCJ, DieppePA, KirwanJR. Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee. Ann Rheum Dis, 2000; 59:71–74.
16.
SpectorTD, HartDJ, NandraD, DoyleDV, MackillopN, GallimoreJR, PepysMB. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum, 1997; 40:723–727.
17.
FelsonDT, ChaissonCE. Understanding the relationship between body weight and osteoarthritis. Baillieres Clinical Rheum, 1997; 11:671–681.
18.
CarmanWJ, SowersM, HawthorneV M, WeissfeldLA. Obesity as a risk factor for osteoarthritis of the hand and wrist: A prospective study. Am J Epidemiol, 1994; 139:119–129.
19.
DahaghinS, Bierma-ZeinstraSM, KoesBW, HazesJM, PolsHA. Do metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam Study. Ann Rheum Dis, 2007; 66:916–920.
20.
Rojas-RodriguezJ, Escobar-LinaresLE, Garcia-CarrascoM, EscarcegaRO, Fuentes-AlexandroS, Zamora-UstaranA. The relationship between the metabolic syndrome and energy-utilization deficit in the pathogenesis of obesity-induced osteoarthritis. Med Hypotheses, 2007; 69:860–868.
21.
HartDJ, DoyleDV, SpectorTD. Association between metabolic factors and knee osteoarthritis in women: The Chingford Study. J Rheumatol, 1995; 22:1118–1123.
22.
SturmerT, BrennerH, BrennerRE, GuntherKP. Non-insulin dependent diabetes mellitus (NIDDM) and patterns of osteoarthritis. The Ulm osteoarthritis study. Scand J Rheumatol, 2001; 30:169–171.
23.
PereiraRM, de CarvalhoJF, BonfaE. Metabolic syndrome in rheumatological diseases. Autoimmun Rev, 2009; 8:415–419.
24.
EngstromG, Gerhardsson de VerdierM, RollofJ, NilssonPM, LohmanderLS. C-reactive protein, metabolic syndrome and incidence of severe hip and knee osteoarthritis. A population-based cohort study. Osteoarthritis Cartilage, 2009; 17:168–173.
25.
MaderR, LaviI. Diabetes mellitus and hypertension as risk factors for early diffuse idiopathic skeletal hyperostosis (DISH)Osteoarthritis Cartilage, 2009; 17:825–828.
26.
UchidaK, UrabeK, NaruseK, OgawaZ, MabuchiK, ItomanM. Hyperlipidemia and hyperinsulinemia in the spontaneous osteoarthritis mouse model, STR/Ort. Exp Anim, 2009; 58:181–187.
27.
HirschR, Lethbridge-CejkuM, HansonR, ScottWWJr, ReichleR, PlatoCC, TobinJD, HochbergMC. Familial aggregation of osteoarthritis: Data from the Baltimore Longitudinal Study on Aging. Arthritis Rheum, 1998; 41:1227–1232.
28.
MacGregorAJ, AntoniadesL, MatsonM, AndrewT, SpectorD. The genetic contribution to radiographic hip osteoarthritis in women: Results of a classic twin study. Arthritis Rheum, 2000; 43:2410–2416.
29.
Botha-ScheepersSA, WattI, SlagboomE, MeulenbeltI, RosendaalFR, BreedveldFC, KloppenburgM. Influence of familial factors on radiologic disease progression over two years in siblings with osteoarthritis at multiple sites: A prospective longitudinal cohort study. Arthritis Rheum, 2007; 57:626–633.
30.
MiyamotoY, MabuchiA, ShiD, KuboT, TakatoriY, SaitoS, FujiokaM, SudoA, UchidaA, YamamotoS, OzakiK, TakigawaM, TanakaT, NakamuraY, JiangQ, IkegawaS. A functional polymorphism in the 5′ UTR of GDF5 is associated with susceptibility to osteoarthritis. Nat Genet, 2007; 39:529–533.
31.
SolovievaS, KämäräinenOP, HirvonenA, HämäläinenS, LaitalaM, VehmasT, LuomaK, NäkkiA, RiihimäkiH, Ala-KokkoL, MännikköM, Leino-ArjasP. Association between interleukin 1 gene cluster polymorphisms and bilateral distal interphalangeal osteoarthritis. J Rheumatol, 2009; 36:1977–1986.
32.
ValdesAM, LoriesRJ, van MeursJB, KerkhofH, DohertyS, HofmanA, HartDJ, ZhangF, LuytenFP, UitterlindenAG, DohertyM, SpectorTD. Variation at the ANP32A gene is associated with risk of hip osteoarthritis in women. Arthritis Rheum, 2009; 60:2046–2054.
33.
Rodriguez-LopezJ, Pombo-SuarezM, LizM, Gomez-ReinoJJ, GonzalezA. Further evidence of the role of frizzled-related protein gene polymorphisms in osteoarthritis. Ann Rheum Dis, 2007; 66:1052–1055.
34.
IliopoulosD, MalizosKN, OikonomouP, TsezouA. Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS One, 2008; 3:e3740.
35.
MobasheriA, VannucciSJ, BondyCA, CarterSD, InnesJF, ArteagaMF, TrujilloE, FerrazI, ShakibaeiM, Martín-VasalloP. Glucose transport and metabolism in chondrocytes: A key to understanding chondrogenesis, skeletal development and cartilage degradation in osteoarthritis. Histol Histopathol, 2002; 17:1239–1267.
36.
RosaSC, GongalvesJ, JudasF, MobasheriA, LopesC, MendesAF. Impaired glucose transporter-1 degradation and increased glucose transport and oxidative stress in response to high glucose in chondrocytes from osteoarthritic versus normal human cartilage. Arthritis Res Ther, 2009; 11:R80.
37.
VlassaraH, BucalaR, StricklerL. Pathogenic effects of AGEs, biochemical, biologic and clinical implications for diabetes and aging. Lab Invest, 1994; 70:138–151.
38.
VerzijlN, DeGrootJ, ZakenCB, Braun-BenjaminO, MaroudasA, BankRA, MizrahiJ, SchalkwijkCG, ThorpeSR, BaynesJW, BijlsmaJW, LafeberFP, TeKoppeleJM. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum, 2002; 46:114–123.
39.
DeGrootJ, VerzijlN, Wenting-van WijkMJ, JacobsKM, van ElB, van RoermundPM, BankRA, BijlsmaJW, TeKoppeleJM, LafeberFP. Accumulation of advanced glycation end products as a molecular mechanism for aging as a risk factor in osteoarthritis. Arthritis Rheum, 2004; 50:1207–1215.
40.
SteenvoordenMM, HuizingaTW, VerzijlN, BankRA, RondayHK, LuningHA, LafeberFP, ToesRE, DeGrootJ. Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum, 2006; 54:253–263.
41.
LoeserRF, YammaniRR, CarlsonCS, ChenH, ColeA, ImHJ, BurschLS, YanSD. Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum, 2005; 52:2376–2385.
42.
BodenG, ShulmanGI. Free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clinical Invest, 2002; 32,Suppl 3:14–23.
43.
VessbyB. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol, 2003; 14:15–19.
44.
StorlienLH, JenkinsAB, ChisholmDJ, PascoeWS, KhouriS, KraegenEW. Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. Diabetes, 1991; 40:280–289.
45.
VessbyB, UnsitupaM, HermansenK, RiccardiG, RivelleseAA, TapsellLC, NalsenC, BerglundL, LouherantaA, RasmussenBM, CalvertGD, MaffetoneA, PedersenE, GustafssonIB, StorlienLH. KANWU Study. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. Diabetologia, 2001; 44:312–319.
46.
MasukoK, MurataM, SuematsuN, OkamotoK, YudohK, NakamuraH, KatoT. A metabolic aspect of osteoarthritis: lipid as a possible contributor to the pathogenesis of cartilage degradation. Clin Exp Rheumatol, 2009; 2:347–253.
47.
PlumbMS, AspdenRM. High levels of fat and (n-6) fatty acids in cancellous bone in osteoarthritis. Lipids Health Dis, 2004; 3:12.
48.
WangY, WlukaAE, HodgeAM, EnglishDR, GilesGG, O'SullivanR, CicuttiniFM. Effect of fatty acids on bone marrow lesions and knee cartilage in healthy, middle-aged subjects without clinical knee osteoarthritis. Osteoarthritis Cartilage, 2008; 16:579–583.
49.
WlukaAE, WangY, Davies-TuckM, EnglishDR, GilesGG, CicuttiniFM. Bone marrow lesions predict progression of cartilage defects and loss of cartilage volume in healthy middle-aged adults without knee pain over 2 yrs. Rheumatology (Oxford), 2008; 47:1392–1396.
50.
SturmerT, SunY, SauerlandS, ZeissigI, GuntherK-P, PuhlW, B rennerH. Serum cholesterol and osteoarthritis. The baseline examination of the Ulm Osteoarthritis Study. J Rheumatol, 1998; 25:1827–1832.
51.
Davies-TuckM, HannaF, DavisSR, BellRJ, DavisonSL, WlukaAE, AdamsJ, CicuttiniFM. Total cholesterol and triglycerides are associated with the development of new bone marrow lesions in asymptomatic middle-aged women—a prospective cohort study. Arthritis Res Ther, 2009; 1:R181.
52.
SoranN, AltindagO, CakirH, CelikH, DemirkolA, AksoyN. Assessment of paraoxonase activities in patients with knee osteoarthritis. Redox Rep, 2008; 13:194–198.
53.
ShenCL, DunnDM, HenryJH, LiY, WatkinsBA. Decreased production of inflammatory mediators in human osteoarthritic chondrocytes by conjugated linoleic acids. Lipids, 2004; 39:161–166.
54.
ZainalZ, LongmanAJ, HurstS, DugganK, CatersonB, HughesCE, HarwoodJL. Relative efficacies of omega-3 polyunsaturated fatty acids in reducing expression of key proteins in a model system for studying osteoarthritis. Osteoarthritis Cartilage, 2009; 17:882–891.
55.
ConaghanPG, V anharantaH, DieppePA. Is progressive osteoarthritis an atheromatous vascular disease?Ann Rheum Dis, 2005; 64:1539–1541.
56.
FindlayDM. Vascular pathology and osteoarthritis. Rheumatology, 2007; 46:1763–1768.
57.
SilveriF, BrecciaroliD, ArgentatiF, CerviniC. Serum levels of insulin in overweight patients with osteoarthritis of the knee. J Rheumatol, 1994; 21:1899–1902.
58.
DesseinPH, StanwixAE, JoffeBI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res, 2002; 4:R5.
59.
PelleymounterMA, CullenMJ, BakerMB, HechtR, WintersD, BooneT, CollinsF. Effects of the obese gene product on body weight regulation in ob/ob mice. Science, 1995; 269:540–553.
60.
LuheshiGN, GardnerJD, RushforthDA, LoudonAS, RothwellNJ. Leptin actions on food intake and body temperature are mediated by IL-1. Proc Natl Acad Sci USA, 1999; 96:7047–7052.
61.
HalaasJL, GajiwalaKS, MaffeiM, CohenSL, ChaitBT, RabinowitzD, LalloneRL, B urleySK, FriedmanJM. Weight-reducing effects of the plasma protein encoded by the obese gene. Science, 1995; 269:543–546.
62.
ConsidineRV, SinhaMK, HeimanML, KriauciunasA, StephensTW, NyceMR, OhannesianJP, MarcoCC, McKeeLJ, BauerTLet al.Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med, 1996; 334:292–295.
63.
HoggardN, MercerJG, RaynerDV, MoarK, TrayhurnP, WilliamsLM. Localization of leptin receptor mRNA splice variants in murine peripheral tissues by RT-PCR and in situ hybridization. Biochem Biophys Res Commun, 1997; 232:383–387.
64.
HynesGR, JonesPJH. Leptin and its role in lipid metabolism. Curr Opin Lipidol, 2001; 12:321–327.
65.
FaggioniR, FeingoldKR, GrunfeldC. Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J, 2001; 15:2565–2571.
66.
GordeladzeJO, DrevonCA, SyversenU, ReselandJE. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem, 2002; 85:825–836.
67.
KumeK, SatomuraK, NishishoS, KitaokaE, YamanouchiK, TobiumeS, NagayamaM. Potential role of leptin in endochondral ossification. J Histochem Cytochem, 2002; 50:159–169.
68.
FigenschauY, KnutsenG, ShahazeydiS, JohansenO, SveinbjörnssonB. Human articular chondrocytes express functional leptin receptors. Biochem Biophys Res Commun, 2001; 287:190–197.
69.
DumondH, PresleN, TerlainB, MainardD, LoeuilleD, NetterP, PottieP. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum, 2003; 48:3118–3129.
70.
SimopoulouT, MalizosKN, IliopoulosD, StefanouN, PapatheodorouL, IoannouM, TsezouA. Differential expression of leptin and leptin's receptor isoform (Ob-Rb) mRNA between advanced and minimally affected osteoarthritic cartilage; effect on cartilage metabolism. Osteoarthritis Cartilage, 2007; 15:872–883.
71.
KernPA, Di GregorioGB, LuT, RassouliN, RanganathanG. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor- expression. Diabetes, 2003; 52:1779–1785.
72.
WeyerC, FunahashiT, TanakaS, HottaK, MatsuzawaY, PratleyRE, TataranniPA. 2001. Hypoadiponectinemia in obesity, type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001; 86:1930–1935.
ChenTH, ChenL, HsiehMS, ChangCP, ChouDT, TsaiSH. Evidence for a protective role for adiponectin in osteoarthritis. Biochim Biophys Acta, 2006; 1762:711–718.
GomezJM, MaravallFJ, GomezN, NavarroMA, CasamitjanaR, SolerJ. Interactions between serum leptin, the insulin-like growth factor-1 system, and sex, age, anthropometric and body composition variables in a healthy population randomly selected. Clin Endocrinol, 2003; 58:213–219.
77.
SandhuMS, HealdAH, GibsonJM, CruickshankJK, DungerDB, WarehamNJ. Circulating concentrations of insulin-like growth factor-1 and development of glucose intolerance: a prospective observational study. Lancet, 2002; 359:1740–1745.
78.
ClemmonsDR, MosesAC, McKayMJ, SommerA, RosenDM, RuckleJ. The combination of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 reduces insulin requirements and insulin-dependent type 1 diabetes: Evidence for in vivo biological activity. J Clin Endocrinol Metab, 2000; 85:1518–1524.
79.
KolaczynskiJW, CaroJF. Insulin-like growth factor-1 therapy in diabetes. Ann Intern Med, 1994; 120:47–55.
80.
CusiK, De FronzoRA. Treatment of NIDDM, IDDM and other insulin resistant states with IGF-1: physiological and clinical considerations. Diabetes Rev, 1995; 3:206–236.
81.
ContiE, CarrozzaC, CapoluongoE, VolpeM, CreaF, ZuppiC, AndreottiF. Insulin-like growth factor-1 as a vascular protective factor. Circulation, 2004; 110:2260–2265.
82.
Martel-PelletierJ, Di BattistaJA, LajeunesseD, PelletierJP. IGF/IGFBP axis in cartilage and bone in osteoarthritis pathogenesis. Inflamm Res, 1998; 47:90–100.
83.
VerschurePJ, MarieJV, JoostenLA, HelsenMM, LafeberFP, BergWB. Localization of insulin-like growth factor-1 receptor in human normal and osteoarthritic cartilage in relation to proteoglycan synthesis and content. Br J Rheumatol, 1996; 35:1044–1055.
84.
MiddletonJ, ArnottN, WalshS, BeresfordJ. Osteoblasts and osteoclasts in adult human osteophyte tissue express the mRNAs for insulin-like growth factors I and II and the type 1 IGF receptor. Bone, 1995; 16:287–293.
85.
MiddletonJF, TylerJA. Upregulation of insulin-like growth factor I gene expression in the lesions of osteoarthritic human articular cartilage. Ann Rheum Dis, 1992; 51:440–447.
86.
OlneyRC, TsuchiyaK, WilsonDM, MohtaiM, MaloneyWJ, SchurmanDJ, SmithRL. Chondrocytes from osteoarthritic cartilage have increased expression of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) and −5, but not IGF-II or IGFBP-4. J Clin Endocrinol Metab, 1996; 81:1096–1103.
87.
TardifG, ReboulP, PelletierJP, GengC, CloutierJM, Martel-PelletierJ. Normal expression of type 1 insulin-like growth factor receptor by human osteoarthritic chondrocytes with increased expression and synthesis of insulin-like growth factor binding protein. Arthritis Rheum, 1996; 39:968–978.
88.
DoréS, PelletierJP, DiBattistaJA, TardifG, BrazeauP, Martel-PelletierJ. Human osteoarthritic chondrocytes possess an increased number of insulin-like growth factor 1 binding sites but are unresponsive to its stimulation. Possible role of IGF-1-binding protein. Arthritis Rheum, 1994; 37:253–263.
89.
WangJ, ElewautD, VeysEM, VerbruggenG. Insulin-like growth factor 1-induced interleukin-1 receptor II overrides the activity of interleukin-1 and controls the homeostasis of the extracellular matrix of cartilage. Arthritis Rheum, 2003; 48:1281–1291.
90.
MassicotteF, FernandesJC, Martel-PelletierJ, PelletierJP, LajeunesseD. Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. Bone, 2006; 38:333–341.
91.
MurataM, YudohK, MasukoK. The potential role of vascular endothelial growth factor (VEGF) in cartilage: how the angiogenic factor could be involved in the pathogenesis of osteoarthritis?Osteoarthritis Cartilage, 2008; 16:274–86.
92.
PfanderD, KortjeD, ZimmermannR, WeselohG, KirschT, GessleinM, CramerT, SwobodaB. Vascular endothelial growth factor in articular cartilage of healthy and osteoarthritic human knee joints. Ann Rheum Dis, 2001; 60:1070–1073.
93.
EnomotoH, InokiI, KomiyaK, ShiomiT, IkedaE, ObataK, MatsumotoH, ToyamaY, OkadaY. Vascular endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. Am J Pathol, 2003; 162:171–181.
Blaney DavidsonEN, van der KraanPM, van den BergWB. TGF-beta and osteoarthritis. Osteoarthritis Cartilage, 2007; 15:597–604.
96.
Blaney DavidsonEN, VittersEL, van der KraanPM, van den BergWB. Expression of transforming growth factor-beta (TGFbeta) and the TGFbeta signalling molecule SMAD-2P in spontaneous and instability-induced osteoarthritis: role in cartilage degradation, chondrogenesis and osteophyte formation. Ann Rheum Dis, 2006; 65:1414–1421.
97.
Pombo-SuarezM, Castaño-OrejaMT, CalazaM, Gomez-ReinoJ, GonzalezA. Differential upregulation of the three transforming growth factor beta isoforms in human osteoarthritic cartilage. Ann Rheum Dis, 2009; 68:568–571.
98.
Van BeuningenHM, GlansbeekHL, van der KraanPM, van den BergWB. Osteoarthritis-like changes in the murine knee joint resulting from intraarticular transforming growth factor-beta injections. Osteoarthritis Cartilage, 2000; 8:25–33.
99.
ScharstuhlA, GlansbeekHL, van BeuningenHM, VittersEL, van der KraanPM, van den BergWB. Inhibition of endogenous TGF-? during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. J Immunol, 2002; 169:507–514.
100.
BrackenCP, WhitelawML, PeetDJ. The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses. Cell Mol Life Sci, 2003; 60:1376–1393.
101.
RatcliffePJ, O'RourkeJF, MaxwellPH, PughCW. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol, 1998; 201,Pt 8:1153–1162.
102.
SemenzaGL. Expression of hypoxia-inducible factor 1: Mechanisms and consequences. Biochem Pharmacol, 2000; 59:47–53.
103.
LafontJE, TalmaS, MurphyCL. Hypoxia-inducible factor 2alpha is essential for hypoxic induction of the human articular chondrocyte phenotype. Arthritis Rheum, 2007; 56:3297–3306.
104.
SchipaniE, RyanHE, DidricksonS, KobayashiT, KnightM, JohnsonRS. Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev, 2001; 15:2865–2876.
105.
CoimbraIB, JimenezSA, HawkinsDF, Piera-VelazquezS, StokesDG. Hypoxia-inducible factor 1alpha expression in human normal and osteoarthritic chondrocytes. Osteoarthritis Cartilage, 2004; 12:336–345.
106.
CramerT, SchipaniE, JohnsonRS, SwobodaB, PfanderD. Expression of VEGF isoforms by epiphyseal chondrocytes during low-oxygen tension is HIF-1 alpha dependent. Osteoarthritis Cartilage, 2004; 12:433–439.
107.
YudohK, NakamuraH, Masuko-HongoK, KatoT, NishiokaK. Catabolic stress induces expression of hypoxia-inducible factor (HIF)-1a in articular chondrocytes: Involvement of HIF-1a in the pathogenesis of osteoarthritis. Arthritis Res Ther, 2005; 7:R904–R914.
108.
BarnesPJ, KarinM. Nuclear factor-kappa B: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 1997; 336:1066–1067.
109.
YamamotoY, GaynorRB. Role of the NF-kappa B pathway in the pathogenesis of human disease states. Curr Mol Med, 2001; 1:287–296.
110.
SoltLA, MayMJ. The IkappaB kinase complex: Master regulator of NF-kappaB signaling. Immunol Res, 2008; 42:3–18.
111.
ShoelsonSE, LeeJ, YuanM. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord, 2003; 27,Suppl 3:S49–S52.
112.
BrandK, PageS, RoglerG, BartschA, BrandlR, KnuechelR, PageM, KaltschmidtC, BaeuerlePA, NeumeierD. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J. Clin. Invest, 1996; 97:1715–1722.
113.
Abu-AmerY, DarwechI, OteroJ. Role of the NF-kappaB axis in immune modulation of osteoclasts and bone loss. Autoimmunity, 2008; 41:204–211.
114.
RosaSC, JudasF, LopesMC, MendesAF. Nitric oxide synthase isoforms and NF-kappaB activity in normal and osteoarthritic human chondrocytes: Regulation by inducible nitric oxide. Nitric Oxide, 2008; 19:276–283.
115.
MarokR, WinyardPG, CoumbeA, KusML, GaffneyK, BladesS, MappPI, MorrisCJ, BlakeDR, KaltschmidtC, BaeuerlePA. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum, 1996; 39:583–591.
116.
ChenLX, LinL, WangHJ, WeiXL, FuX, ZhangJY, YuCL. Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. Osteoarthritis Cartilage, 2008; 16:174–184.
117.
RayA, RayBK. An inflammation-responsive transcription factor in the pathophysiology of osteoarthritis. Biorheology, 2008; 45:399–409.
118.
RayA, KurokiK, CookJL, BalBS, KenterK, AustG, RayBK. Induction of matrix metalloproteinase 1 gene expression is regulated by inflammation-responsive transcription factor SAF-1 in osteoarthritis. Arthritis Rheum, 2003; 48:134–145.
WilliamsIL, WheatcroftSB, ShahAM, KearneyMT. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes Relat Metab Disord, 2002; 26:754–764.
122.
FeronO, DessyC, MoniotteS, DesagerJP, BalligandJL. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest, 1999; 103:897–905.
123.
OemarBS, TschudiMR, GodoyN, BrovkovichV, MalinskiT, LuscherTF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation, 1998; 97:2494–2498.
124.
VuolteenahoK, MoilanenT, KnowlesRG, MoilanenE. The role of nitric oxide in osteoarthritis. Scand J Rheumatolol, 2007; 36:247–258.
125.
ScherJU, PillingerMH, AbramsonSB. Nitric oxide synthases and osteoarthritis. Current Rheumatol Rep, 2007; 9:9–15.
126.
AbramsonSB. Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res Ther, 2008; 10,Suppl 2:S2.
127.
AminAR, Di CesarePE, VyasP, AtturM, TzengE, BilliarTR, StuchinSA, AbramsonSB. The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: Evidence for up-regulated neuronal nitric oxide synthase. J Exp Med, 1995; 182:2097–2102.
128.
MelchiorriC, MeliconiR, FrizzieroL, SilvestriT, PulsatelliL, MazzettiI, BorziRM, UguccioniM, FacchiniA. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum, 1998; 41:2165–2174.
129.
LeGrandA, FermorB, FinkC, PisetskyDS, WeinbergJB, VailTP, GuilakF. Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum, 2001; 44:2078–2083.
130.
TaskiranD, Stefanovic-RacicM, GeorgescuH, EvansC. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun, 1994; 200:142–148.
131.
SasakiK, HattoriT, FujisawaT, TakahashiK, InoueH, TakigawaM. Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J Biochem, 1998; 123:431–439.
132.
MendesAF, CarvalhoAP, CaramonaMM, LopesMC. Role of nitric oxide in the activation of NF-kappaB, AP-1 and NOS II expression in articular chondrocytes. Inflamm Res, 2002; 51:369–375.
133.
XiaW, SzomorZ, WangY, MurrellGA. Nitric oxide enhances collagen synthesis in cultured human tendon cells. J Orthop Res, 2006; 24:159–172.
134.
GoldringMB. Osteoarthritis and cartilage: The role of cytokines. Curr Rheumatol Rep, 2000; 2:459–465.
135.
FernandesJC, Martel-PelletierJ, PelletierJP. The role of cytokines in osteoarthritis pathophysiology. Biorheology, 2002; 39:237–246.
136.
BenitoMJ, VealeDJ, FitzGeraldO, van den BergWB, BresnihanB. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis, 2005; 64:1263–1267.
137.
DelboscS, PaizanisE, MagousR, AraizC, DimoT, CristolJP, CrosG, AzayJ. Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis, 2005; 179:43–49.
138.
YamaguchiY, YoshikawaN, KagotaS, NakamuraK, HaginakaJ, KunitomoM. Elevated circulating levels of markers of oxidative-nitrative stress and inflammation in a genetic rat model of metabolic syndrome. Nitric Oxide, 2006; 15:380–386.
139.
RobertsCK, BarnardRJ, SindhuRK, JurczakM, EhdaieA, VaziriND. Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism, 2006; 55:928–934.
140.
FordES, MokdadAH, GilesWH, BrownDW. The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes, 2003; 52:2346–2352.
141.
MeigsJB, LarsonMG, FoxCS, Keaney JFJr, VasanRS, BenjaminEJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: The Framingham Offspring Study. Diabetes Care, 2007; 30:2529–2535.
142.
FujitaK, NishizawaH, FunahashiT, ShimomuraI, ShimabukuroM. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J, 2006; 70:1437–1442.
143.
FurukawaS, FujitaT, ShimabukuroM, IwakiM, YamadaY, NakajimaY, NakayamaO, MakishimaM, MatsudaM, ShimomuraI. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest, 2004; 114:1752–1761.
144.
EspositoK, CiotolaM, SchisanoB, MissoL, GiannettiG, CerielloA, GuiglinoD. Oxidative stress in the metabolic syndrome. J Endocrinol Invest, 2006; 29:791–795.
145.
GrattaglianoI, PalmieriVO, PortincasaP, MoschettaA, PalascianoG. Oxidative stress-induced risk factors associated with the metabolic syndrome: A unifying hypothesis. J Nutr Biochem, 2008; 19:491–504.
146.
RobertsCK, SindhuKK. Oxidative stress and metabolic syndrome. Life Sci, 2009; 84:705–712.
147.
YudohK, NguyenT, NakamuraH, Hongo-MasukoK, KatoT, NishiokaK. Potential involvement of oxidative stress in cartilage senescence and development of osteoarthritis: Oxidative stress induces chondrocyte telomere instability and downregulation of chondrocyte function. Arthritis Res Ther, 2005; 7:R380–R391.
148.
LoeserRF. Aging and osteoarthritis: The role of chondrocyte senescence and aging changes in the cartilage matrix. Osteoarthritis Cartilage, 2009; 17:971–979.
149.
FulleS, ProtasiF, Di TanoG, PietrangeloT, BeltraminA, BoncompagniS, VecchietL, FanòG. The contribution of reactive oxygen species to sarcopenia and muscle ageing. Exp Gerontol, 2004; 39:17–24.
150.
BragaM, Sinha HikimAP, DattaS, FerriniMG, BrownD, KovachevaEL, Gonzalez-CadavidNF, Sinha-HikimI. Involvement of oxidative stress Caspase 2-mediated intrinsic pathway signaling in age-related increase in muscle cell apoptosis in mice. Apoptosis, 2008; 13:822–832.
151.
TodaY, SegalN, TodaT, KatoA, TodaF. A decline in lower extremity lean body mass per body weight is characteristic of women with early phase osteoarthritis of the knee. J Rheumatol, 2000; 27:2449–2454.
ParanH, ShargianL, ShwartzI, GutmanM. Long-term follow-up on the effect of silastic ring vertical gastroplasty on weight and co-morbidities. Obes Surg, 2007; 17:737–741.
154.
SultanS, ParikhM, YounH, KurianM, FieldingG, RenC. Early U.S. outcomes after laparoscopic adjustable gastric banding in patients with a body mass index less than 35 kg/m2. Surg Endosc, 2009; 23:1569–1573.
155.
Abu-AbeidS, WishnitzerN, SzoldA. The influence of surgically-induced weight loss on the knee joint. Obes Surg, 2005; 15:1437–1442.
